Intrahepatic Cholangiocarcinoma Clinical Trials 2023
Browse 99 Intrahepatic Cholangiocarcinoma Medical Studies Across 273 Cities
9 Phase 3 Trial · 964 Intrahepatic Cholangiocarcinoma Clinics
Reviewed by Michael Gill, B. Sc.
Tele Health Exercise Prehabilitationfor Bile Duct Cancer
This trial tests if exercise can help people with liver cancer prepare for surgery better. #Exercise #Cancer #Health
Has No Placebo
Moffitt Cancer CenterMohammed Al-Jumayli, MD
Durvalumabfor Bile Duct Cancer
This trial is testing a new immunotherapy treatment for pancreatic, liver, and biliary tract cancer. The treatment consists of two drugs, durvalumab and tremelimumab, given in combination with propranolol and, in some cases, chemotherapy.
Cross Cancer Institute
NGM438for Oral Squamous Cell Carcinoma
Grand Rapids, MI
This trial is testing a new cancer drug, NGM438, as a possible treatment for advanced or metastatic solid tumors.
START Midwest (+4 Sites)NGM Biopharmaceuticals, Inc
ELU001for Ovarian Tumors
San Antonio, TX
This trial is focused on subjects with advanced, recurrent or refractory FRα overexpressing tumors. ELU001 is a new chemical entity consisting of payloads and targeting moieties covalently bound by linkers to the C'Dot particle carrier. This is the first trial of its kind and a novel molecular entity.
Phase 1 & 2
New Experimental Therapeutics of San Antonio (NEXT Oncology) (+12 Sites)Eliel Bayever, MBBCh, MRCPElucida Oncology
Tivozanibfor Bile Duct Cancer
This trial will test if the cancer drug tivozanib can safely and effectively treat cholangiocarcinoma.
Phase 1 & 2
National Institutes of Health Clinical CenterJonathan M Hernandez, M.D.
Drug ICP-192for Bladder Cancer
This trial is testing a new cancer drug, ICP-192, on patients with advanced solid tumors and FGFR gene alterations. The trial has two parts, with the first part testing different doses of the drug to see what is safe and effective, and the second part expanding the study to more patients.
Phase 1 & 2
Arizona Oncology (+8 Sites)Beijing InnoCare Pharma Tech Co., Ltd.
Discontinue PD-1/PD-L1-1 Inhibitorfor Bile Duct Cancer
This trial will study whether it is better to stop treatment with PD-1/PD-L1 therapy after one year or continue until disease progression.
UPMC Hillman Cancer CenterJason Luke, MD
Olaparibfor Isocitrate Dehydrogenase
This trial will test the effectiveness of a new combination of drugs to treat patients with IDH-mutated solid tumors.
Princess Margaret Cancer CentreEric Chen, M.D.
Pembrolizumabfor Anal Cancer
Los Angeles, CA
This trial is testing a new immunotherapy drug for people with advanced cancer who have progressed on standard of care therapy.
Call for Information (Investigational Site 0202) (+10 Sites)Medical DirectorMerck Sharp & Dohme Corp.
Dose Escalation Phasefor Skin Cancer
This trial tests a new cancer drug to find if it's safe, how it works, and if it's effective against advanced solid tumors.
Sarah Cannon Research Institute - CO (+4 Sites)Abi Vainstein-HarasSapience Therapeutics
10 Intrahepatic Cholangiocarcinoma Clinical Trials Near Me
Top Hospitals for Intrahepatic Cholangiocarcinoma Clinical Trials
Memorial Sloan Kettering Cancer Center
25All Time Trials for Intrahepatic Cholangiocarcinoma
2000First Intrahepatic Cholangiocarcinoma Trial
Massachusetts General Hospital
19All Time Trials for Intrahepatic Cholangiocarcinoma
2006First Intrahepatic Cholangiocarcinoma Trial
MD Anderson Cancer Center
15All Time Trials for Intrahepatic Cholangiocarcinoma
2011First Intrahepatic Cholangiocarcinoma Trial
The University of Texas MD Anderson Cancer Center
11All Time Trials for Intrahepatic Cholangiocarcinoma
2014First Intrahepatic Cholangiocarcinoma Trial
Top Cities for Intrahepatic Cholangiocarcinoma Clinical TrialsIntrahepatic Cholangiocarcinoma Clinical Trials by Phase of Trial
N/A Intrahepatic Cholangiocarcinoma Clinical TrialsIntrahepatic Cholangiocarcinoma Clinical Trials by Age Group
10Active Intrahepatic Cholangiocarcinoma Clinical Trials
10Number of Unique Treatments
9Number of Active Locations
18+ Intrahepatic Cholangiocarcinoma Clinical TrialsMost Recent Intrahepatic Cholangiocarcinoma Clinical Trials
98Active Intrahepatic Cholangiocarcinoma Clinical Trials
Top Treatments for Intrahepatic Cholangiocarcinoma Clinical Trials
Began Recruiting Date
Gemcitabine + Cisplatin + Durvalumab + Yttrium-90 Selective Internal Radiation Therapy for Intrahepatic Cholangiocarcinoma
Recently Completed Studies with FDA Approved Treatments for Intrahepatic Cholangiocarcinoma
Active Intrahepatic Cholangiocarcinoma Clinical Trials
All Time Trials for Intrahepatic Cholangiocarcinoma
First Recorded Intrahepatic Cholangiocarcinoma Trial
National Cancer Institute (NCI)
Trifluridine and Tipiracil Hydrochloride
National Cancer Institute (NCI)
EMD Serono Research & Development Institute, Inc.
Part 1 TPST-1120
Forma Therapeutics, Inc.
University of Florida
References1 Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. https://pubmed.ncbi.nlm.nih.gov/152735422 Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae. https://pubmed.ncbi.nlm.nih.gov/152735423 Levy PL, Gros A. Fast track to personalized TCR T cell therapies. Cancer Cell. 2022 May 9;40(5):447-449. doi: 10.1016/j.ccell.2022.04.013. Epub 2022 May 9. https://pubmed.ncbi.nlm.nih.gov/355374084 Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, Pruitt SK, Leary A. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3. https://pubmed.ncbi.nlm.nih.gov/309431245 Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, Rugo HS, de Braud F, Varga AI, Hansen A, Wang H, Krishnan S, Norwood KG, Doi T. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020 Oct 15;147(8):2190-2198. doi: 10.1002/ijc.33013. Epub 2020 May 2. https://pubmed.ncbi.nlm.nih.gov/323590916 Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4. https://pubmed.ncbi.nlm.nih.gov/316825507 Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, D'Angelica M, DeMatteo RP, Fong Y, Schwartz L, Kemeny N, O'Reilly E, Abou-Alfa GK, Shimada H, Blumgart LH, Jarnagin WR. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008 Jul;248(1):84-96. doi: 10.1097/SLA.0b013e318176c4d3. https://pubmed.ncbi.nlm.nih.gov/185802118 Dai C, Liang S, Sun B, Kang J. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. Front Endocrinol (Lausanne). 2020 Dec 11;11:608422. doi: 10.3389/fendo.2020.608422. eCollection 2020. Review. https://pubmed.ncbi.nlm.nih.gov/333627229 Talreja JP, Kahaleh M. Photodynamic therapy for cholangiocarcinoma. Gut Liver. 2010 Sep;4 Suppl 1(Suppl 1):S62-6. doi: 10.5009/gnl.2010.4.S1.S62. Epub 2010 Sep 10. https://pubmed.ncbi.nlm.nih.gov/2110329710 Talreja JP, DeGaetani M, Sauer BG, Kahaleh M. Photodynamic therapy for unresectable cholangiocarcinoma: contribution of single operator cholangioscopy for targeted treatment. Photochem Photobiol Sci. 2011 Jul;10(7):1233-8. doi: 10.1039/c0pp00259c. Epub 2011 Apr 21. https://pubmed.ncbi.nlm.nih.gov/21512706